Nab‐Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non‐Small Cell Lung Cancer. (6th April 2015)

• Record Type: Journal Article
• Authors: Lammers, Philip Edward; Lu, Bo; Horn, Leora; Shyr, Yu; Keedy, Vicki
• Is Part Of: Oncologist. Volume 20:Number 5(2015)
• Page Start: 491
• Page End: 492
• Publication Date: 2015-04-06
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2015-0030
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract : Lessons Learned: The concomitant use of weekly nab ‐paclitaxel and carboplatin with concurrent radiotherapy was demonstrated to be a safe therapeutic approach in this phase I trial of 10 evaluable patients with stage III NSCLC. Despite the lack of systemic glucocorticoids, there were no reported infusion reactions or cases of peripheral neuropathy in this trial, both of which are known to occur with the use of paclitaxel. Background: Unresectable stage III non‐small cell lung cancer (NSCLC) has a 5‐year survival rate of 20%, and concurrent chemoradiotherapy results in significant toxicity with the use of current chemotherapeutic agents. nab ‐Paclitaxel was approved by the U.S. Food and Drug Administration in October 2012 for use along with carboplatin in advanced NSCLC. This study was undertaken to determine the maximum tolerated dose and dose‐limiting toxicities (DLTs) of weekly nab ‐paclitaxel given in combination with carboplatin and concurrent radiotherapy in patients with unresectable stage III NSCLC. Methods: Escalating doses of once‐weekly nab ‐paclitaxel were given along with once‐weekly carboplatin area under the plasma concentration time curve (AUC) of 2 and concurrent radiotherapy 66 Gy in 33 fractions, followed by 2 cycles of carboplatin and nab ‐paclitaxel consolidation chemotherapy. Results: Eleven patients were enrolled and received treatment per protocol, with 10 evaluable for efficacy and toxicity. At dose level 1 ( nab ‐paclitaxel 60 mg/m 2 ), 2 DLTs were observed: esophagitis and radiation dermatitis. Six patients were enrolled at dose level 0 ( nab ‐paclitaxel 40 mg/m 2 ) with no DLTs. Nine of 10 evaluable patients had a partial response. Conclusion: Concurrent chemoradiotherapy with nab ‐paclitaxel 40 mg/m 2 and carboplatin AUC 2 is a safe and well‐tolerated therapeutic regimen in patients with stage III NSCLC. A separate phase I/II study to evaluate the efficacy of this regimen is under way. Abstract : 摘要 背景 . 不可切除的III期非小细胞肺癌（NSCLC）5年生存率为20%，而使用当前的化疗药物实行同期放化疗可导致明显的毒性。美国食品和药物监督管理局（FDA）在2012年批准白蛋白结合型紫杉醇可与卡铂联合治疗进展期NSCLC。本研究旨在确定每周一次白蛋白结合型紫杉醇联合卡铂及同期放疗在不可切除的III期NSCLC患者中的最大耐受剂量和剂量限制毒性（DLT）。 方法 . 白蛋白结合型紫杉醇每周一次给药，剂量逐渐上调；卡铂给药剂量为血浆浓度时间曲线（AUC）= 2；同期放疗为66 Gy剂量分33次照射。随后给予2周期卡铂和白蛋白结合型紫杉醇巩固化疗。 结果 . 研究共纳入11例患者，并按方案给予治疗。其中10例可评价有效性和毒性。在剂量水平为1（白蛋白结合型紫杉醇60 mg/m 2 ）时，观察到2起DLT：食管炎和放射性皮炎。剂量水平为0（白蛋白结合型紫杉醇40 mg/m 2 ）时纳入的6例患者中无一发生DLT。10例可评价患者中有9例达到部分缓解。 结论 . 对于III期NSCLC患者，白蛋白结合型紫杉醇40 mg/m 2 和卡铂AUC 2联合同期放化疗是安全且耐受良好的治疗方案。另一项I/II期研究正在评价这一方案的有效性。 The Oncologist 2015;20:491–492